Maze Therapeutics (NASDAQ:MAZE) Insider Phillips Courtney Sells 1,981 Shares of Stock

Posted by Geri Gentry on Sep 5th, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) insider Phillips Courtney sold 1,981 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $26.47, for a total transaction of $52,437.07. Following the completion of the transaction, the insider owned 9,019 shares of the company’s stock, valued at approximately $238,732.93. This trade represents a 18.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Phillips Courtney also recently made the following trade(s):

On Thursday, September 3rd, Phillips Courtney sold 2,012 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total value of $52,332.12.

Maze Therapeutics Trading Up 1.3%

Shares of NASDAQ:MAZE opened at $26.21 on Friday. The business’s 50 day moving average price is $28.69 and its 200-day moving average price is $31.17. Maze Therapeutics, Inc. has a 1 year low of $14.27 and a 1 year high of $53.65. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, equities research analysts forecast that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. TRV GP IV LLC purchased a new position in shares of Maze Therapeutics in the second quarter valued at $133,502,907. ARCH Venture Management LLC acquired a new position in shares of Maze Therapeutics in the second quarter valued at approximately $122,983,582. BlackRock Inc. purchased a new position in shares of Maze Therapeutics during the 2nd quarter worth $104,525,000. Jupiter Topco LLC purchased a new position in Maze Therapeutics during the second quarter worth about $101,764,000. Finally, Janus Henderson Group PLC boosted its position in shares of Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after acquiring an additional 2,390,713 shares during the last quarter.

Analysts Set New Price Targets

MAZE has been the subject of several recent research reports. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, August 12th. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $66.00.

Check Out Our Latest Report on MAZE

Maze Therapeutics News Roundup

Here are the key news stories impacting Maze Therapeutics this week:

Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

About Maze Therapeutics

(Get Free Report)

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.